COMMUNIQUÉS West-GlobeNewswire

Albireo Reports Third Quarter 2017 Financial Results

14/11/2017 - 14:00

— Executing towards planned A4250 Phase 3 PFIC trial — — Decision on potential approval of elobixibat in Japan expected in the first half of 2018 — BOSTON, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ [...]

Gallup and Sharecare Release New Research on the Cost of Diabetes to U.S. Communities and Employers

14/11/2017 - 14:00

WASHINGTON and ATLANTA, Nov. 14, 2017 (GLOBE NEWSWIRE) -- World-leading analytics and advice firm, Gallup, and Sharecare, the digital health company helping people manage all their health in one place, have released new [...]

Cannabix Technologies makes “50 B.C. Innovations to Watch List” with Marijuana Breathalyzer, Added to CSE25 Index

14/11/2017 - 14:00

VANCOUVER, British Columbia, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE:BLO) (OTC PINK:BLOZF) (the “Company or Cannabix”), developer of the Cannabix Marijuana Breathalyzer for law enforcement and [...]

Mateon Provides Corporate Update and Reports Third Quarter 2017 Financial Results

14/11/2017 - 14:00

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, today [...]

PositiveID Reports Third Quarter 2017 Results; Revenues increase 38% Year over Year

14/11/2017 - 14:00

DELRAY BEACH, Fla., Nov. 14, 2017 (GLOBE NEWSWIRE) -- PositiveID Corporation (OTC:PSID), a life sciences company focused on detection and diagnostics, announced today its financial results for the quarter ended [...]

EyeGate Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update

14/11/2017 - 14:00

WALTHAM, Mass., Nov. 14, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG ) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies [...]

Poseida Therapeutics Presents on the Development of Allogeneic and Autologous BCMA-Specific CAR-T Therapies at Precision: Blood Cancer Summit

14/11/2017 - 14:00

SAN DIEGO, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Poseida Therapeutics, Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, will participate [...]

Actinium Pharmaceuticals Launches the AWE Program aka Actinium Warhead Enabling Program to Enable Collaborations Based on Its Actinium-225 Technology Platform

14/11/2017 - 14:00

- AWE Program launched post successful demonstration of Actinium’s “Biobetter” capabilities as evidenced by superior experimental results with actinium-225 labeled daratumumab when compared to unlabeled daratumumab, a [...]

Former General Mills Executive Joins Canadian Startup as Advisor

14/11/2017 - 14:00

PETERBOROUGH, Ontario, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Noblegen Inc. (“Noblegen”) — announces the appointment of distinguished industry veteran, Jim Kirkwood, as an official advisor to the Corporation. Kirkwood is a [...]

Intra-Cellular Therapies Presents Data on Mechanism of Action of Lumateperone and ITI-214 at the 2017 Society for Neuroscience (SfN) Annual Meeting

14/11/2017 - 14:00

NEW YORK, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI ), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today [...]

BioSig Technologies Adds Role of Chief Regulatory and Compliance Officer in Preparation for FDA Submission

14/11/2017 - 14:00

Santa Monica, CA, Nov. 14, 2017 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet [...]

Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial Results

14/11/2017 - 14:00

Completed Successful EMA Meeting for DCCR in Prader-Willi Syndrome Continued Preparations to Begin Phase III Program Presented Positive Updated Safety and Efficacy Data from Pilot Clinical Trial of DCCR for Treatment of [...]

Zogenix to Present at Stifel 2017 Healthcare Conference

14/11/2017 - 14:00

EMERYVILLE, Calif., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX ), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that [...]

ProQR Prices Approximately $20 Million Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary Shares

14/11/2017 - 13:44

LEIDEN, The Netherlands, Nov. 14, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR ), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicines for the [...]

Zynerba Pharmaceuticals Reports Third Quarter 2017 Financial Results and Operational Highlights

14/11/2017 - 13:30

DEVON, Pa., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ: ZYNE ), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically- [...]

XBiotech Announces Presentation of Novel Findings for MABp1 in the Prevention of Coronary Thrombosis at the American Heart Association Scientific Sessions

14/11/2017 - 13:30

AUSTIN, Texas, Nov. 14, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT ) announced today a presentation of findings on the role of IL-1 alpha (IL-1α) associated with Neutrophil Extracellular Traps (NETs) in [...]

Cesca Therapeutics to Present at the Advanced Cell Therapy Shanghai Summit 2017

14/11/2017 - 13:30

RANCHO CORDOVA, Calif., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ: KOOL ), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that [...]

Strongbridge Biopharma plc Provides Corporate Update and Reports Third Quarter 2017 Financial Results

14/11/2017 - 13:30

~ Achieved Net Product Sales of $2.5 Million for KEVEYIS ® (dichlorphenamide) , a 67% Revenue Growth Increase over the Previous Quarter ~ ~ Increasing Commercial Investment in KEVEYIS with Expansion of Sales Force and [...]

ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update

14/11/2017 - 13:01

- All Three Development Compounds Progressing with Key Clinical Milestones Over the Next 12 Months - Geneva, Switzerland and Boston, MA - November 14, 2017 - ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical [...]